Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nexalin Technology (NXL) EBT (2021 - 2026)

Nexalin Technology has reported EBT over the past 5 years, most recently at -$2.4 million for Q4 2025.

  • For Q4 2025, EBT rose 16.13% year-over-year to -$2.4 million; the TTM value through Dec 2025 reached -$8.2 million, down 8.0%, while the annual FY2025 figure was -$8.2 million, 8.0% down from the prior year.
  • EBT for Q4 2025 was -$2.4 million at Nexalin Technology, down from -$2.3 million in the prior quarter.
  • Over five years, EBT peaked at -$303646.0 in Q3 2022 and troughed at -$2.8 million in Q4 2024.
  • A 5-year average of -$1.4 million and a median of -$1.2 million in 2024 define the central range for EBT.
  • Biggest five-year swings in EBT: skyrocketed 83.34% in 2022 and later plummeted 656.54% in 2023.
  • Year by year, EBT stood at -$595928.0 in 2021, then dropped by 23.02% to -$733113.0 in 2022, then fell by 6.49% to -$780669.0 in 2023, then tumbled by 262.95% to -$2.8 million in 2024, then increased by 16.13% to -$2.4 million in 2025.
  • Business Quant data shows EBT for NXL at -$2.4 million in Q4 2025, -$2.3 million in Q3 2025, and -$1.6 million in Q2 2025.